Pepys, Mark B.

C-reactive protein: a critical update

Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation

Biomarkers in Disease MechanismsAdipokines, Inflammation, and Metabolic Diseases

Cited by 3,436

C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease

Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease Prognosis

Cited by 2,953

The physiological structure of human C-reactive protein and its complex with phosphocholine

Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure

Biomarkers in Disease MechanismsComplement system in diseases

Cited by 818

Targeting C-reactive protein for the treatment of cardiovascular disease.

Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., et al. (2006) · Nature

Biomarkers in Disease MechanismsComplement system in diseases

Cited by 672

Effect of alcohol consumption on systemic markers of inflammation

Imhof, A., Froehlich, M., Brenner, H., Boeing, H., Pepys, M. B., & Koenig, W. (2001) · The Lancet

Alcohol Consumption and Health EffectsSubstance Abuse Treatment and Outcomes

Cited by 559

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 540

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis

Tennent, G. A., Lovat, L. B., & Pepys, M. B. (1995) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 438

Low‐level increases in serum C‐reactive protein are present in early osteoarthritis of the knee and predict progressive disease

Spector, T. D., Hart, D. J., Nandra, D., Doyle, D. V., Mackillop, N., Gallimore, J. R., & Pepys, M. B. (1997) · Arthritis & Rheumatism

Osteoarthritis Treatment and MechanismsRheumatoid Arthritis Research and Therapies

Cited by 403

Human plasma fibrinogen is synthesized in the liver

Tennent, G. A., Brennan, S. O., Stangou, A. J., O'Grady, J., Hawkins, P. N., & Pepys, M. B. (2007) · Blood

Amyloidosis: Diagnosis, Treatment, OutcomesBlood properties and coagulation

Cited by 304

Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene

Botto, M., Hawkins, P. N., Bickerstaff, M. C. M., Herbert, J., Bygrave, A. E., Mcbride, A., Hutchinson, W. L., Tennent, G. A., Walportz, M. J., & Pepys, M. B. (1997) · Nature Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 266

Amyloid P component. A critical review

Pepys, M. B., Booth, D. R., Hutchinson, W. L., Gallimore, J. R., Collins, I. M., & Hohenester, E. (1997) · Amyloid

Biomarkers in Disease MechanismsComplement system in diseases

Cited by 181

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

Richards, D. B., Cookson, L. M., Barton, S. V., Liefaard, L., Lane, T., Hutt, D. F., Ritter, J. M., Fontana, M., Moon, J. C., Gillmore, J. D., et al. (2018) · Science Translational Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesPrion Diseases and Protein Misfolding

Cited by 136

Complement factor H binds to denatured rather than to native pentameric C-reactive protein

Hakobyan, S., Harris, C. L., van den Berg, C. W., Fernandez-Alonso, M. C., de Jorge, E. G., de Cordoba, S. R., Rivas, G., Mangione, P., Pepys, M. B., & Morgan, B. P. (2008) · Journal of Biological Chemistry

Complement system in diseasesBiomarkers in Disease Mechanisms

Cited by 90

The Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs

Pepys, M. B. (2018) · Frontiers in Immunology

Biomarkers in Disease MechanismsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 67

Human Serum Amyloid P Component is a Single Uncomplexed Pentamer in Whole Serum

Hutchinson, W. L., Hohenester, E., & Pepys, M. B. (2000) · Molecular Medicine

Biomarkers in Disease MechanismsProtein purification and stability

Cited by 66

Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo

Al-Shawi, R., Tennent, G. A., Millar, D. J., Richard-Londt, A., Brandner, S., Werring, D. J., Simons, J. P., & Pepys, M. B. (2016) · Open Biology

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 26

Serum amyloid P component (not Serum Amyloid Protein)

Pepys, M. B. (1999) · Nature Medicine

Systemic Lupus Erythematosus ResearchBiomarkers in Disease Mechanisms

Cited by 11

Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders

Schmidt, A. F., Finan, C., Chopade, S., Ellmerich, S., Rossor, M. N., Hingorani, A. D., & Pepys, M. B. (2024) · Open Biology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 11